BEAM vs JNJ · rev $32.2M vs P/E 17, rev $49.37B
Beam Therapeutics Inc (BEAM) versus Johnson & Johnson (JNJ) — a side-by-side from cached financials, not a winner call.
Beam Therapeutics Inc (BEAM) is a biotechnology company listed on US.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Latest reported BEAM revenue for 2026-06-30 was $32.2M. Net income was -$217.0M. Revenue was up 1.5% from 2026-03-31 to 2026-06-30. BEAM currently screens at market cap $2.01B.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
BEAM currently screens at market cap $2.01B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Not investment advice. Open the BEAM and JNJ stock pages for the full models.
Not investment advice.